TIL · Instil Bio, Inc.
$7.86
+0.03 (+0.38%)
At close · Aug 27
Going-concern doubt
— cleared Aug 13, 2026
The latest filing states the doubt was alleviated.
“the 2024 Loan is due in January 2027, for total principal of $85.6 million, which is in excess of cash, cash equivalents, and marketable securities on hand as of June 30, 2026, which we concluded is an indicator of substantial doubt about our ability to continue as a going concern. ... We concluded that management's plans, including Complex Therapeutics LLC's contractual right to exercise the extension option to January 2028, which is within Complex Therapeutics LLC's control, alleviate the conditions that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$53.10M
Shares
6.78M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2021
Net Income
-$71.37M
+3.7%
FY2025
Operating Margin
-24379.71%
FY2020
Diluted EPS
-$10.70
+6.1%
FY2025
Operating Cash Flow
-$36.62M
+34.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $0 | $138K | |
| $8.97M | $8.97M | $4.27M | $0 | — | — | — | |
| $13.56M | $24.74M | $11.84M | $39.6M | $141.06M | $107.25M | $19.4M | |
| $22.43M | $27.22M | $44.21M | $47.55M | $62.24M | $48.31M | $14.38M | |
| — | $534K | $3.61M | $4.76M | $5.99M | $2.75M | $256K | |
| $37.17M | $78.58M | $73.54M | $159.17M | $226.46M | $155.56M | $33.78M | |
| -$37.17M | -$78.58M | -$73.54M | -$159.17M | -$226.46M | -$155.56M | -$33.64M | |
| — | — | — | — | — | — | -24379.71% | |
| — | -$78.05M | -$69.93M | -$154.41M | -$220.47M | -$152.81M | -$33.39M | |
| $6.28M | $5.83M | $8.99M | $5.21M | $1.88M | $0 | — | |
| -$365K | $212K | -$2.86M | -$575K | -$564K | -$1.28M | -$3.94M | |
| — | -$71.37M | -$74.14M | -$156.09M | -$225.25M | -$156.76M | -$37.59M | |
| — | $0 | — | $0 | -$2.07M | $39K | $151K | |
| -$30.28M | -$71.37M | -$74.14M | -$156.09M | -$223.18M | -$156.79M | -$37.74M | |
| — | — | — | — | — | — | -27346.38% | |
| -$30.06M | -$71.73M | -$74.02M | -$155.94M | -$223.58M | -$156.6M | -$38.02M | |
| USD/shares | -$4.39 | -$10.70 | -$11.39 | -$24.00 | -$34.46 | -$29.60 | -$47.20 |
| USD/shares | -$4.39 | -$10.70 | -$11.39 | -$24.00 | -$34.46 | -$29.60 | -$47.20 |
| shares | — | 6.67M | 6.51M | 6.5M | 6.48M | 5.3M | 799.89K |
| shares | — | 6.67M | 6.51M | 6.5M | 6.48M | 5.3M | 799.89K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.52×
EV/EBIT
—
Peer median 12.48×
P/E (TTM)
—
Peer median 8.71×
Peer medians compare against the 287 similar-size Biotechnology companies (of 534 listed).
Key facts
CIK
1789769
CUSIP
45783C200
13F (30d)
25 filings
25 filers
Visit website
Investor relations